Ultra-accurate sequencing to find single- and double-strand DNA changes
Ultra-High Fidelity Single-Molecule Profiling of Mosaic Double- and Single-Strand DNA Mutations and Damage
A new ultra-accurate DNA reading method (HiDEF-seq) designed to find tiny one-strand or two-strand mutations and damage in human tissues that may relate to cancer and aging.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11329250 on NIH RePORTER |
What this research studies
Researchers are building a way to read individual DNA molecules without copying them so they can see rare mistakes and damage that affect only one DNA strand. The method, called HiDEF-seq, uses very accurate long-read sequencing to detect both single-strand and double-strand changes that current tests miss. The team will develop and refine the technology at NYU as part of the SMaHT Network and apply it to human tissue samples to build a catalog of somatic mosaic mutations. This work aims to map how these tiny DNA changes accumulate with age and disease to help guide future research.
Who could benefit from this research
Good fit: Ideal participants would be people able to provide tissue or blood samples at participating centers, such as patients with cancer, people undergoing biopsies or surgeries, or volunteers donating tissues for research.
Not a fit: People looking for immediate new treatments should not expect direct clinical benefit from this technology development project.
Why it matters
Potential benefit: If successful, this could enable earlier or more precise detection and study of cancer-related or age-related DNA changes, improving diagnosis and research pathways.
How similar studies have performed: Existing high-fidelity methods detect mutations present on both DNA strands, but this amplification-free, single-molecule approach is novel and largely untested for detecting single-strand damage in human tissues.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Evrony, Gilad David — New York University School of Medicine
- Study coordinator: Evrony, Gilad David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.